Plus readouts from Jasper, Dyne and more

Bispecifics, ADCs and more compete to become the next-generation of EGFR-targeting agents

Biotech engineers its antibody-drug conjugates to unbind their target upon internalization, recycling it back to the cell surface to recruit more ADCs

J&J to bring Rybrevant into two Phase III colorectal cancer studies based on Phase II data

Shanghai biotech partners with stealthy Foresite newco Vignette to advance T cell engager for autoimmune disease

Plus: Astellas’ Vyloy on track to become EU’s first CLDN18.2 therapy, and 11 products likely headed for label expansions

Part 2 of an interview with AstraZeneca’s head of oncology

April opinions also include earlier-line use of J&J’s Rybrevant and BMS’s Opdivo

Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs

Pharma sees opportunities for label expansions as it builds pipeline, gains commercial presence in solid tumors